AU2020287549B2 - Therapeutic for gout or hyperuricemia - Google Patents

Therapeutic for gout or hyperuricemia

Info

Publication number
AU2020287549B2
AU2020287549B2 AU2020287549A AU2020287549A AU2020287549B2 AU 2020287549 B2 AU2020287549 B2 AU 2020287549B2 AU 2020287549 A AU2020287549 A AU 2020287549A AU 2020287549 A AU2020287549 A AU 2020287549A AU 2020287549 B2 AU2020287549 B2 AU 2020287549B2
Authority
AU
Australia
Prior art keywords
group
administration
pharmaceutically acceptable
acceptable salt
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020287549A
Other languages
English (en)
Other versions
AU2020287549A1 (en
Inventor
Masuharu Hirano
Shiro Kobayashi
Eri MIYAYAMA
Takashi Ohta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Publication of AU2020287549A1 publication Critical patent/AU2020287549A1/en
Application granted granted Critical
Publication of AU2020287549B2 publication Critical patent/AU2020287549B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020287549A 2019-06-04 2020-06-04 Therapeutic for gout or hyperuricemia Active AU2020287549B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-104534 2019-06-04
JP2019104534 2019-06-04
PCT/JP2020/022039 WO2020246528A1 (ja) 2019-06-04 2020-06-04 痛風又は高尿酸血症の治療薬

Publications (2)

Publication Number Publication Date
AU2020287549A1 AU2020287549A1 (en) 2022-01-27
AU2020287549B2 true AU2020287549B2 (en) 2026-01-29

Family

ID=73653292

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020287549A Active AU2020287549B2 (en) 2019-06-04 2020-06-04 Therapeutic for gout or hyperuricemia

Country Status (8)

Country Link
US (1) US20220323441A1 (https=)
EP (1) EP3981469B1 (https=)
JP (2) JPWO2020246528A1 (https=)
KR (1) KR20220016861A (https=)
CN (1) CN113924145A (https=)
AU (1) AU2020287549B2 (https=)
CA (1) CA3149714A1 (https=)
WO (1) WO2020246528A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121648131A (zh) * 2020-12-08 2026-03-13 学校法人东日本学园 细胞内atp增强剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757610A1 (en) * 2004-06-14 2007-02-28 Nippon Chemiphar Co., Ltd. Condensed pyrimidine derivative and xanthine oxidase inhibitor
JP2016520133A (ja) * 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2019107412A1 (ja) * 2017-11-28 2019-06-06 静岡県公立大学法人 固体分散体
WO2019208635A1 (ja) * 2018-04-27 2019-10-31 日本ケミファ株式会社 縮合ピリミジン誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019104534A (ja) 2017-12-13 2019-06-27 大日本印刷株式会社 ロール体梱包箱

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757610A1 (en) * 2004-06-14 2007-02-28 Nippon Chemiphar Co., Ltd. Condensed pyrimidine derivative and xanthine oxidase inhibitor
JP2016520133A (ja) * 2013-05-31 2016-07-11 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物
WO2019107412A1 (ja) * 2017-11-28 2019-06-06 静岡県公立大学法人 固体分散体
WO2019208635A1 (ja) * 2018-04-27 2019-10-31 日本ケミファ株式会社 縮合ピリミジン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAMBOSI G. et al.: "Challenges to improve the biopharmaceutical properties of poorly water-soluble drugs and the application of the solid dispersion technology", REVISTA MATÉRIA, 2018, vol. 23, no. 4, article e-12224 *

Also Published As

Publication number Publication date
WO2020246528A1 (ja) 2020-12-10
CA3149714A1 (en) 2020-12-10
KR20220016861A (ko) 2022-02-10
AU2020287549A1 (en) 2022-01-27
JP2025061775A (ja) 2025-04-11
EP3981469A1 (en) 2022-04-13
EP3981469B1 (en) 2024-11-20
JPWO2020246528A1 (https=) 2020-12-10
US20220323441A1 (en) 2022-10-13
EP3981469A4 (en) 2023-06-21
CN113924145A (zh) 2022-01-11

Similar Documents

Publication Publication Date Title
KR102024955B1 (ko) 치환된 시클로부텐디온 항염 화합물의 콜린 염
EP3718548B1 (en) Solid dispersion
JP2025061775A (ja) 痛風又は高尿酸血症の治療薬
CA3201273A1 (en) Intracellular atp enhancer
HK40073463A (en) Therapeutic for gout or hyperuricemia
HK40073463B (en) Therapeutic for gout or hyperuricemia
JP6903252B2 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
WO2020048449A1 (zh) 包含1,3,5-三嗪衍生物或其盐的固体药物组合物
HK40098529A (zh) 固体分散体
HK40027115B (zh) 固体分散体
AU2017251803A1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
AU2006207396A1 (en) Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof